Lonza's mammalian expression technologies offer commercially viable systems that cover the diversity of complex proteins and are suitable for large-scale development. The combinatorial screening uses a broad range of genetic elements that mitigate the lack of predictability for both the quantity and quality of your target protein. This, combined with extensive experience in establishing customized product-specific assay methods that aid in cell line decisions, gives you the tools you need to be successful in a biopharmaceutical landscape that presents both new challenges as well as exciting opportunities.

  • Rebecca Michael, PhD. Head of Cell & Molecular Biology, Lonza
  • Nathalie Knabe, Head of Strategic Marketing, Mammalian, Lonza

Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center